BioCentury
ARTICLE | Clinical News

Sucampo's cobiprostone misses Phase IIa reflux endpoint

April 20, 2016 1:00 AM UTC

Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) said it will discontinue development of cobiprostone ( SPI-8811) to treat proton pump inhibitor (PPI)-refractory non-erosive reflux disease (NERD) or symptomatic gastroesophageal reflux disease (sGERD) after the compound missed the primary endpoint in a Phase IIa study. The prostone chloride channel 2 ( CLCN2; CIC-2) agonist failed to improve heartburn symptoms as determined by patient-reported outcomes, the 153-patient study's primary endpoint.

Next half, Sucampo expects results of a futility analysis of an ongoing Phase IIa study of cobiprostone to prevent oral mucositis in head and neck cancer patients receiving concurrent radiation and chemotherapy. The compound has Fast Track designation to prevent oral mucositis. ...